Targeted drug trametinib tested on rare BRAF cancers
NCT ID NCT04439279
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests the drug trametinib in 35 patients with advanced cancers that have certain BRAF mutations or fusions. The goal is to see if trametinib can shrink or stop cancer growth by blocking proteins that help cancer cells grow. The study focuses on patients whose cancers have not responded to other treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trametinib (Mekinist)
What this could lead to
If successful, this could provide a targeted treatment option for patients with certain BRAF mutations or fusions that are not covered by existing therapies.
What could go wrong
This is a small, early-phase trial with only 35 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects like heart rhythm issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States